C
C. Stroh
Researcher at Merck & Co.
Publications - 11
Citations - 324
C. Stroh is an academic researcher from Merck & Co.. The author has contributed to research in topics: Cetuximab & KRAS. The author has an hindex of 6, co-authored 11 publications receiving 308 citations.
Papers
More filters
Journal ArticleDOI
Relationship of efficacy with KRAS status (wild type versus mutant) in patients with irinotecan-refractory metastatic colorectal cancer (mCRC), treated with irinotecan (q2w) and escalating doses of cetuximab (q1w): The EVEREST experience (preliminary data)
S. Tejpar,Marc Peeters,Yves Humblet,Jan B. Vermorken,G. De Hertogh,W. De Roock,Johannes Nippgen,A. von Heydebreck,C. Stroh,E. Van Cutsem +9 more
TL;DR: This work has shown that in pts with mCRC after failure of irinotecan-based therapy, the efficacy could be improved by escalating the dose of cetuximab, and this work aims to demonstrate this in patients with a prior history of central giant cell granuloma.
Journal ArticleDOI
Cetuximab with chemotherapy (CT) as first-line treatment for metastatic colorectal cancer (mCRC): Analysis of the CRYSTAL and OPUS studies according to KRAS and BRAF mutation status.
TL;DR: A pooled analysis of the CRYSTAL and OPUS pt populations evaluated overall survival (OS), progression-free survival (PFS), and best overall response (OR) using updated data for all efficacy endpoints according to KRAS/BRAF mutation status.
Journal ArticleDOI
6077 A meta-analysis of the CRYSTAL and OPUS studies combining cetuximab with chemotherapy (CT) as 1st-line treatment for patients (pts) with metastatic colorectal cancer (mCRC): Results according to KRAS and BRAF mutation status
TL;DR: The meta-analysis of 845 pts with KRAS wt tumors demonstrated that the addition of cetuximab to CT provided a signifi cant benefi t for the primary study endpoints PFS and OR and for OS compared with pts receiving CT alone.
Journal ArticleDOI
Predictive biomarkers to improve treatment of metastatic colorectal cancer (mCRC): Outcomes with cetuximab plus FOLFIRI in the CRYSTAL trial
C.-H. Köhne,D. Stroiakovski,C. R. Changchien,R. Lim,Tamás Pintér,G. Bodoky,C. Stroh,Ilhan Celik,Ph. Rougier,E. Van Cutsem +9 more
TL;DR: The benefits of adding cetuximab to CT were greater in KRAS wt pts than ITT pts for all clinically relevant endpoints, and KRAS is a key biomarker for selecting a targeted therapy combined with standard CT in first-line mCRC.
Patent
Biomarkers and methods for determining efficacy of anti-egfr antibodies in cancer therapy
C. Stroh,Anja von Heydebreck +1 more
TL;DR: In this article, a biomarkers based on gene expression products and methods for determining the efficacy of anti-EGFR antibodies in the treatment of EGFR expressing cancer were proposed. And the authors proposed a method to predict the sensitivity or resistance of a patient suffering from EGFR-expressing cancer to the treatment with a specific anti- EGFR antibody.